Pakistan Press International
ISLAMABAD: World Breastfeeding Week is being observed from today (Monday), to create awareness about the importance of breastfeeding for health of children.
According to World Health Organization (WHO), initiation of breastfeeding within the first hour of birth and its continuation for up to two years or beyond offers a powerful line of defence against all forms of child malnutrition. Breastfeeding also acts as babies’ first vaccine, protecting them against many common childhood illnesses.
ISLAMABAD: The death toll in flood affected districts of Balochistan has risen to 136, while 70 persons have been injured.
According to a report released by the Provincial Disaster Management Authority, a total of 13,535 houses were collapsed or partially damaged due to the ongoing heavy rains and floods. Six highways covering 640 kilometers have also been severely affected in the rains and flood. Meanwhile, large-scale relief and rehabilitation operations are underway in all affected areas of the province.
ISLAMABAD: In Indian Illegally Occupied Jammu and Kashmir (IIOJK), the All Parties Hurriyat Conference (APHC) reiterating its call for a complete shutdown on 5th August, has appealed the people to offer special prayers for the success of the ongoing freedom movement.
According to reports, the incarcerated Vice Chairman, Ghulam Ahmad Gulzar, in a special message from Srinagar Central Jail said that 05 August is one of the most tragic days of modern Kashmir history and the Kashmiris will always observe it as exploitation day, day of mourning and as a black day.
He said it was on 05 August in 2019 when RSS-backed fascist government led by Narendra Modi usurped all basic rights of Kashmiris and turned IIOJK into a big open-air prison. The APHC General Secretary, Molvi Bashir Ahmad Irfani in a statement said Kashmiris will prefer martyrdom over Hindutva slavery.
KARACHI: The judicial magistrate (East) Monday rejected the request of the investigation officer (IO) for the medical examination of Dua Zehra.
The investigation officer sought time from the judicial magistrate for the submission of the interim challan. The judicial magistrate directed the investigation officer to submit the interim challan on August 6 next.
Today, Zaheer Ahmed, the main accused in Dua Zehra abduction case, along with his brother Shabbir, appeared before the Additional District and Sessions Court (East). The court had also issued orders for the production of Dua Zehra too. On April 16, Dua’s parents filed an FIR at a Karachi police station that their daughter had been kidnapped while disposing of house trash.
On April 26, Dua was recovered from Okara in Punjab after hectic search by police. Later, she told SHC that she had not been kidnapped but left Karachi on her own and married with Zaheer in Punjab of her free will. Later, a special medical board determined that Dua Zehra’s age is between 15 and 16 years, but nearer to 15 years.
QUETTA: Nine more people lost lives to the rains and floods in Balochistan on Monday.
According to a Provincial Disaster Management Authority (PDMA) report, the death toll due to torrential rains and floods in the province had reached 136. Those who lost their lives in the recent heavy rains and floods include 56 men, 33 women, and 47 children. Most deaths have been reported in Bolan, Quetta, Zhob, Dukki, and Khuzdar.
Hundreds of houses have been turned into piles of rubble by rains and floods, and thousands of people are forced to spend days and nights under the open sky. The flood-hit people are also facing a shortage of food and water.
KARACHI: Educational institutions, including schools and colleges, reopened in Sindh today (Monday) from August 1, 2022 after summer vacations of two months ended.
Both government and private schools and colleges have reopened across Sindh as per a notice issued by the provincial School Education and Literacy Department. However, attendance of the students in educational institutes was less as in some areas of Sindh, water has not been drained out from the schools so far, due to which the continuity of classes could be affected.
As part of the anti-dengue campaign, special instructions have been given by the government for sanitation and drainage in educational institutions so as to ensure health atmosphere for students.
WALTHAM, Mass and SHANGHAI, China, July 31, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, announced that it has received approval of its Investigational New Drug (IND) application from the National Medical Products Administration (NMPA) of China for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). The main objective of the Phase 1/2 is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001.
TED is a debilitating vison-threatening autoimmune disease that causes inflammation and fibrosis within the orbit of the eye. With no approved therapies for TED patients in China, treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 is a differentiated humanized monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R) intended for the treatment of TED.
“We are proud that the IND application for ZB001 was approved by the NMPA about two months following its submission, highlighting our team’s unique ability to efficiently execute on our development programs,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “We are excited to work with leading clinical experts in China to accelerate the development of ZB001 to address the significant unmet clinical need in thyroid eye disease.”
Zenas BioPharma licensed the exclusive rights to develop, manufacture and commercialize ZB001 (Viridian VRDN-001) and other compounds targeting IGF-1R in non-oncology indications in the greater China area from Viridian Therapeutics, Inc. (Viridian) in October 2020. After submitting an IND for VRDN-001 to the U.S. Food and Drug Administration in October 2021, Viridian initiated a Phase 1/2 clinical trial in December 2021 to evaluate proof of concept in TED patients in North America and released encouraging interim healthy volunteer data suggesting robust activity with excellent safety and tolerability of the candidate product.
About Zenas BioPharma
Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and commercialization of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.
Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com